Trial Profile
A phase 1 study of a combination chemotherapy, Sorafenib and intrahepatic arterial infusion of IA-call (DDP-H), for advanced hepatocellular carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Cisplatin
- Indications Liver cancer
- Focus Adverse reactions
- 19 Jan 2012 New trial record